PCI Biotech Financials
| PCIB Stock | NOK 1.33 0.07 5.56% |
PCI |
PCI Biotech Stock Summary
PCI Biotech competes with Tysnes Sparebank, Sparebank, Odfjell Drilling, Odfjell Technology, and Bien Sparebank. PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization technology platform. PCI Biotech Holding ASA was founded in 2000 and is headquartered in Oslo, Norway. PCI BIOTECH operates under Pharmaceuticals And Biosciences classification in Norway and is traded on Oslo Stock Exchange. It employs 11 people.| Instrument | Norway Stock View All |
| Exchange | Oslo Stock Exchange |
| ISIN | NO0010405640 |
| Business Address | Ullernchausseen 64, Oslo |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.pcibiotech.com |
| Phone | (47) 67 11 54 00 |
| Currency | NOK - Kroner |
You should never invest in PCI Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of PCI Stock, because this is throwing your money away. Analyzing the key information contained in PCI Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
PCI Biotech Key Financial Ratios
There are many critical financial ratios that PCI Biotech's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that PCI Biotech Holding reports annually and quarterly.PCI Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining PCI Biotech's current stock value. Our valuation model uses many indicators to compare PCI Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PCI Biotech competition to find correlations between indicators driving PCI Biotech's intrinsic value. More Info.PCI Biotech Holding is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PCI Biotech's earnings, one of the primary drivers of an investment's value.PCI Biotech Holding Systematic Risk
PCI Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. PCI Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on PCI Biotech Holding correlated with the market. If Beta is less than 0 PCI Biotech generally moves in the opposite direction as compared to the market. If PCI Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PCI Biotech Holding is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PCI Biotech is generally in the same direction as the market. If Beta > 1 PCI Biotech moves generally in the same direction as, but more than the movement of the benchmark.
PCI Biotech Thematic Clasifications
PCI Biotech Holding is part of IT investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains
This theme covers Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains. Get More Thematic Ideas
| IT | View |
PCI Biotech March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of PCI Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PCI Biotech Holding. We use our internally-developed statistical techniques to arrive at the intrinsic value of PCI Biotech Holding based on widely used predictive technical indicators. In general, we focus on analyzing PCI Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PCI Biotech's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.36 | |||
| Information Ratio | 0.0429 | |||
| Maximum Drawdown | 41.05 | |||
| Value At Risk | (7.35) | |||
| Potential Upside | 8.73 |
Other Information on Investing in PCI Stock
PCI Biotech financial ratios help investors to determine whether PCI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PCI with respect to the benefits of owning PCI Biotech security.